183 related articles for article (PubMed ID: 35572194)
1. Chimeric anti-GPC3 sFv-CD3ε receptor-modified T cells with IL7 co-expression for the treatment of solid tumors.
Sun Y; Dong Y; Sun R; Liu Y; Wang Y; Luo H; Shi B; Jiang H; Li Z
Mol Ther Oncolytics; 2022 Jun; 25():160-173. PubMed ID: 35572194
[TBL] [Abstract][Full Text] [Related]
2. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
[TBL] [Abstract][Full Text] [Related]
3. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
Huang W; Liu Y; Hu Y; Gao J
Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
[TBL] [Abstract][Full Text] [Related]
4. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
5. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
[TBL] [Abstract][Full Text] [Related]
7. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
[TBL] [Abstract][Full Text] [Related]
8. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.
Zhou L; Li Y; Zheng D; Zheng Y; Cui Y; Qin L; Tang Z; Peng D; Wu Q; Long Y; Yao Y; Wong N; Lau J; Li P
Mol Ther Oncol; 2024 Jun; 32(2):200817. PubMed ID: 38882528
[TBL] [Abstract][Full Text] [Related]
9. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay.
Cao G; Zhang G; Liu M; Liu J; Wang Q; Zhu L; Wan X
Biochem Biophys Rep; 2022 Sep; 31():101324. PubMed ID: 36032401
[TBL] [Abstract][Full Text] [Related]
10. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
[TBL] [Abstract][Full Text] [Related]
11. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma.
Guan L; Wu S; Zhu Q; He X; Li X; Song G; Zhang L; Yin X
Biochem Biophys Rep; 2024 Sep; 39():101741. PubMed ID: 38881757
[TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
13. Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy.
Wu W; Zhou Q; Masubuchi T; Shi X; Li H; Xu X; Huang M; Meng L; He X; Zhu H; Gao S; Zhang N; Jing R; Sun J; Wang H; Hui E; Wong CC; Xu C
Cell; 2020 Aug; 182(4):855-871.e23. PubMed ID: 32730808
[TBL] [Abstract][Full Text] [Related]
14. GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.
Sun RX; Liu YF; Sun YS; Zhou M; Wang Y; Shi BZ; Jiang H; Li ZH
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38750075
[TBL] [Abstract][Full Text] [Related]
15. Development of GPC3-CAR-NK cells and optimization as a therapy for HCC.
Cao B; Ni Q; Chen Z; Yang S; Zhang X; Su H; Zhang Z; Zhao Q; Zhu X; Liu M
J Leukoc Biol; 2024 Jun; ():. PubMed ID: 38922297
[TBL] [Abstract][Full Text] [Related]
16. DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2D.
Li S; Zhao R; Zheng D; Qin L; Cui Y; Li Y; Jiang Z; Zhong M; Shi J; Li M; Wang X; Tang Z; Wu Q; Long Y; Hu D; Wang S; Yao Y; Liu S; Yang LH; Zhang Z; Tang Q; Liu P; Li Y; Li P
Mol Ther Oncolytics; 2022 Sep; 26():15-26. PubMed ID: 35784403
[TBL] [Abstract][Full Text] [Related]
17. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
Lo AS; Ma Q; Liu DL; Junghans RP
Clin Cancer Res; 2010 May; 16(10):2769-80. PubMed ID: 20460472
[TBL] [Abstract][Full Text] [Related]
18. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers.
Steffin D; Ghatwai N; Montalbano A; Rathi P; Courtney AN; Arnett AB; Fleurence J; Sweidan R; Wang T; Zhang H; Masand P; Maris JM; Martinez D; Pogoriler J; Varadarajan N; Thakkar SG; Lyon D; Lapteva N; Mei Z; Patel K; Lopez-Terrada D; Ramos C; Lulla P; Armaghany T; Grilley BJ; Dotti G; Metelitsa LS; Heslop HE; Brenner MK; Sumazin P; Heczey A
Res Sq; 2024 Apr; ():. PubMed ID: 38645165
[TBL] [Abstract][Full Text] [Related]
20. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro.
Huang Y; Zeng J; Liu T; Xu Q; Song X; Zeng J
Cancer Manag Res; 2020; 12():3247-3255. PubMed ID: 32440221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
